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A B S T R A C T
Background
Proliferative vitreoretinopathy (PVR) is a significant cause of failure in retinal reattachment surgery. Various pharmacological agents
have shown potential benefit in reducing postoperative PVR risk.
Objectives
This review aimed to compare the use of intravitreal low molecular weight heparin (LMWH) alone or with 5-Fluorouracil (5-FU)
versus placebo, as an adjunct in the prevention of PVR following retinal reattachment surgery.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group
Trials Register) (The Cochrane Library 2010, Issue 5), MEDLINE (January 1950 to May 2010), EMBASE (January 1980 to May
2010), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com) and ClinicalTrials.gov (http://clinicaltrials.gov).
There were no language or date restrictions in the search for trials. The electronic databases were last searched on 24 May 2010.
Selection criteria
We only included randomised controlled trials (RCTs) that compared intravitreal LMWH alone or with 5-FU, versus placebo for the
prevention of postoperative PVR in patients undergoing primary vitrectomy for rhegmatogenous retinal detachment repair.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data. The review authors contacted study authors for additional
information.
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Main results
We included two RCTs (with a total of 789 participants) comparing LMWH with 5-FU infusion and placebo. However, we did not
perform a meta-analysis because of significant heterogeneity between these studies. One study found a significant beneficial effect
of LMWH with 5-FU in reducing postoperative PVR compared to placebo (RR: 0.48, 95% confidence interval: 0.25 to 0.92),
in 174 patients who were viewed at high-risk of developing postoperative PVR. The other study included 615 unselected cases of
rhegmatogenous retinal detachment and could not show a difference between LMWH with 5-FU infusion and placebo in reducing
PVR rates (RR:1.45, 95% confidence interval: 0.76 to 2.76).
Authors’ conclusions
Results from this review indicate that there is inconsistent evidence from two studies on patients at different risk of PVR on the effect
of LMWH and 5-FU used during vitrectomy to prevent PVR. Future research should be conducted on high risk patients only, until a
benefit is confirmed at least in this patient subgroup.
P L A I N L A N G U A G E S U M M A R Y
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following
retinal reattachment surgery
Proliferative vitreoretinopathy (PVR) is a retinal scarring process which occurs following retinal detachment. It is a major cause of
failure of retinal reattachment surgery and impairment of ultimate visual recovery. Low weight molecular heparin (LMWH) and 5-
Fluorouracil (5-FU) are agents that can be used during surgery to potentially reduce the amount of PVR following surgery.
The two studies included in this review looked at using LMWHwith 5-FU during retinal detachment repair to see if there was an effect
of reducing PVR levels after surgery. One study focused on patients who are considered at high-risk of developing PVR after surgery
because of pre-existing ocular features, and found beneficial effects of this treatment in this group. The other study looked at a wider
group of patients and did not find a benefit in using this combination treatment, and in certain patients the treatment was associated
with poorer vision. Due to the inconsistency of the evidence, until further data are available, future research on the use of LMWH with
5-FU should be conducted only in retinal detachment patients who are likely to develop considerable retinal scarring after surgery.
B A C K G R O U N D
Description of the condition
Proliferative vitreoretinopathy (PVR) is defined as the growth and
contraction of cellular membranes within the vitreous cavity and
on both sides of the retinal surfaces. It is an anomalous scarring
process in retinal detachments (Rachal 1979; SSG 1992). The
condition is the result of proliferation of glial and retinal pigment
epithelial cells, both of which normally act as supporting cells for
the retina. The retinal epithelial cells change their function to be-
come fibroblast-like cells, normally involved inwound healing and
scarring, with contractile properties. The resultant tissue fibrosis
and contracture distorts the inner retina resulting in further re-
detachment. A retinal detachment can be defined as a separation
of the neurosensory retina from the underlying retinal pigment
epithelium.
Retinal reattachment is achieved with one operation in 70.7%
of cases, and after one or more operations in 97.5% of cases
(Heimann 2006). Proliferative vitreoretinopathy is the most com-
mon cause of failed surgery for rhegmatogenous retinal detach-
ment (Rachal 1979; SSG 1992). Rhegmatogenous retinal detach-
ment can be defined as a retinal detachment occurring due to a
retinal break or tear that allows the liquid vitreous to pass through
the break and detach the retina. This is the most common type of
detachment.
Description of the intervention
A high success rate in primary retinal detachment surgery remains
the basis for the prevention of PVR. In cases that develop PVR,
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and in others identified initially as high-risk, the use of adjunc-
tive medical agents is potentially of value in increasing surgical
success rates. There are a number of studies showing a potential
benefit from a variety of pharmacological interventions, includ-
ing retinoic acid (Araiz 1993; Campochiaro 1991; Fekrat 1995;
Verstraeten 1992), dexamethasone (Hui 1993; Tano 1980; Tano
1981), colchicines (Kirmani 1983; Lemor 1986), paclitaxel (taxol)
(Daniels 1990; vanBockxmeer 1985), daunorubicin (Wiedemann
1987; Wiedemann 1991), and 5-Fluorouracil (5-FU) with hep-
arin (Asaria 2001; Kumar 2003).
How the intervention might work
Low molecular weight heparin (LMWH) has been shown to re-
duce postoperative fibrin after vitrectomy (Iverson 1991). Hep-
arin binds to fibronectin and to a wide range of growth factors,
including acidic and basic fibroblast growth factors and platelet-
derived growth factors (Blumenkranz 1992). 5-FU inhibits DNA
synthesis, inhibits fibroblast proliferation and has been effective in
reducing rates of PVR in animal models (Blumenkranz 1984). 5-
FU and LMWH have actions at different stages of the PVR pro-
cess, and using these agents in conjunction may produce a syner-
gistic effect.
Why it is important to do this review
Neither intravitreal LMWHnor 5-FU are in routine clinical use in
retinal detachment procedures, and a systematic review may help
to ascertain whether routine clinical use of such interventions are
beneficial.
O B J E C T I V E S
To compare intravitreal LMWH alone or with 5-FU to placebo
as an adjunct in the prevention of PVR following retinal reattach-
ment surgery.
The null hypothesis is that there is no difference between intrav-
itreal LMWH or 5-FU versus placebo as an adjunct for the pre-
vention of PVR following retinal reattachment surgery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) only.
Types of participants
We included people who were aged 16 years or older and were un-
dergoing primary vitrectomy surgery for rhegmatogenous retinal
detachments. We excluded participants who had posterior pene-
trating trauma, proliferative diabetic retinopathy, corneal opacity
sufficient to impair surgical view, premenopausal status (potential
teratogenic risk) or previous vitrectomy (Asaria 2001).
Types of interventions
We considered the following interventions:
1. Intravitreal LMWH (added to vitrectomy infusion fluid).
2. Adjuvant intravitreal LMWH and 5-FU (added to vitrectomy
infusion fluid).
3. Placebo (control group) - normal vitrectomy infusion fluid (bal-
anced salt solution).
Types of outcome measures
Primary outcomes
The development of postoperative PVR. This was determined
at follow-up visits with complete retinal examination within six
months postoperatively. The presence or absence of PVR and the
reattachment status of the retina were recorded.
Definitions and grading of PVR may vary in the included trials.
We recorded the variations in the definitions and noted whether
the outcome was measured using a validated technique in the
’Characteristics of included studies’ table.
The gold standard for defining and grading PVR is the new adap-
tation of the Retinal Society Classification described by the Sili-
cone Study Group (Lean 1989). The 1983 Retina Society classifi-
cation was modified in 1989 by the Silicone Study Group, whose
classification differentiates between posterior and anterior forms
of PVR and recognises three patterns of proliferation: diffuse, fo-
cal and subretinal.
Secondary outcomes
Reoperation rate and change in visual acuity within six months
postoperatively.
Adverse effects (severe, minor)
Intraoperative ocular haemorrhage, postoperative ocular haemor-
rhage and retinal redetachment rate.
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Economic data
The cost of combined LMWH and 5-FU is $6.00 (Asaria 2001).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (which contains the Cochrane Eyes and Vi-
sion Group Trials Register) (The Cochrane Library 2010, Issue
5), MEDLINE (January 1950 to May 2010), EMBASE (Jan-
uary 1980 to May 2010), the metaRegister of Controlled Tri-
als (mRCT) (www.controlled-trials.com) and ClinicalTrials.gov (
http://clinicaltrials.gov). There were no language or date restric-
tions in the search for trials. The electronic databases were last
searched on 24 May 2010.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
mRCT (Appendix 4) and ClinicalTrials.gov (Appendix 5 ).
Searching other resources
The lead author searched the reference lists of the studies included
in the review for information about further trials. We did not
handsearch journals or conference proceedings specifically for the
review.
Data collection and analysis
Selection of studies
Two authors, working independently, assessed the titles and ab-
stracts resulting from the searches. The full copy of all possibly
or definitely relevant studies were obtained for further assessment.
Both authors assessed these full copies to see if they did indeed
meet the inclusion criteria. The lead author contacted study au-
thors for clarification of any details necessary in order to make a
complete assessment of the relevance of a study.
Data extraction and management
We extracted data from each study, ensuring that the patients met
the criteria described above under participants, and looked at the
outcome measures described above. We looked at dichotomous
data for the primary outcomes and at continuous data for the sec-
ondary outcomes listed above. The unit of analysis was an indi-
vidual person.
Data were entered into RevMan 5 by two authors working inde-
pendently and checked in RevMan 5. We approached the trial au-
thors for information on missing data or where data were difficult
to determine from the full copy of the paper.
We extracted the following study characteristics from each study
included:
1. Methods: method of allocation, masking (participant,
provider, outcome), exclusions after randomisation, losses to
follow-up and compliance, unusual study design.
2. Participants: country where participants enrolled, number
randomised, age, sex, main inclusion and exclusion criteria.
3. Interventions: treatment, comparison intervention
(control), duration of intervention.
4. Outcomes: relevant outcomes on which data were collected
in the trial and length of follow-up.
5. Notes: additional details relevant to that particular trial (e.g.
funding sources).
Assessment of risk of bias in included studies
We assessed all full copies for inclusion in the review for method-
ological quality according to Chapter 8 of the Cochrane Handbook
for Systematic Reviews of Interventions 5.0.1 (Higgins 2009). We
considered five parameters of quality:
1. Randomisation sequence generation
2. Allocation concealment
3. Masking of surgeon and patients
4. Incomplete outcome data
5. Selective reporting
We assessed each parameter of trial quality and graded it as yes
(low risk of bias), no (high risk of bias) or unclear.
Measures of treatment effect
For dichotomous outcomes we calculated a summary relative risk.
We calculated amean difference for continuous outcomes.Wewill
calculate a standardized mean difference if different scales are used
to measure continuous outcomes in studies found when updating
this review (Deeks 2009).
Unit of analysis issues
We did not expect such an issue to be found because these inter-
vention are generally unilateral.
Dealing with missing data
When there were missing data in a study, unless causes of missing-
ness could not be associated to treatment allocation such as death
or patient refused surgery, we used Stata software 11.0 metamiss
macro (White 2008) to explore the impact of missing data assum-
ing fixed and opposite informative missing odds ratio (IMOR) 2
or 1/2.
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Assessment of heterogeneity
The inconsistency of effect estimates across studies was assessed
using the I2 statistic and the Chi2 test for heterogeneity. If the I2
statistic was greater than 50% we considered that to be substantial
heterogeneity.
Assessment of reporting biases
If a sufficient number of studies is found (10 or more) in the
updates of this review, we will examine the symmetry of the funnel
plot to explore small study and publication bias.
Data synthesis
For future updates to this review, data analysis will be performed
according to the guidelines inChapter 9 of theCochrane Handbook
for Systematic Reviews of Interventions (Deeks 2009).
If the I2 statistic is greater than 50% and if there is significant
clinical heterogeneity we will not conduct a meta-analysis. Instead
we will present a tabulated or narrative summary, or both. If the I
2 statistic is less than 50%, there is no significant clinical hetero-
geneity and there is no funnel plot asymmetry, wewill combine the
effect estimates in a meta-analysis using a random-effects model.
We will use a fixed-effect model if there is no statistical or clinical
heterogeneity and if the number of trials is fewer than three. This
is to avoid reporting less robust effect estimates that may result
from random-effects models in situations with very few trials.
Subgroup analysis and investigation of heterogeneity
For future updates of this review, we will conduct subgroup anal-
yses to investigate for heterogeneity if more studies are found and
meta-analysis is possible. The subgroups will be based on: high
versus low risk of PVR among controls (greater than 10%), at-
tached versus detached macula, methods and timing used to de-
liver 5-FU.
Sensitivity analysis
For future updates to this review, we will conduct sensitivity anal-
yses to evaluate the impact of variations in definitions of outcomes
used in different included trials. We will exclude studies graded
as ’no’ (high risk of bias) and ’unclear’ in assessment of method-
ological quality. We will examine the impact of excluding studies
of lower methodological quality, unpublished data, and industry-
funded studies. We will examine whether the summary effect esti-
mate is influenced by any assumptions that have been made dur-
ing the review.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The electronic searches revealed 309 articles, of which, we identi-
fied two RCTs that met our inclusion criteria and were included in
the review (Asaria 2001; Wickham 2007). We rejected two papers
after obtaining the full text copies (Scheer 2005, Wang 2006).
The other 305 articles were either not RCTs or did not specifi-
cally concern patients undergoing primary vitrectomy for retinal
detachment, and were rejected by viewing their abstract alone.
Included studies
Two trials (Asaria 2001; Wickham 2007) were included in the
review and details are given below. See the ’Characteristics of
included studies’ table for more details.
Types of participants
Asaria 2001 recruited 174 patients undergoing primary vitrec-
tomy for rhegmatogenous retinal detachments. All patients were
more than 16 years of age and were deemed at high-risk of de-
veloping PVR. A regression formula derived from previous stud-
ies performed in the groups’ department was used to identify pa-
tients at high-risk of developing PVR. Risk factors for developing
PVR in descending importance were aphakia, preoperative PVR,
size of detachment, anterior uveitis, previous cryotherapy and vit-
reous haemorrhage. Exclusion criteria were posterior penetrating
trauma, proliferative diabetic retinopathy, corneal opacity suffi-
cient to impair surgical view, premenopausal status, previous vit-
rectomy, inability to complete follow-up program and unwilling-
ness to accept randomisation. Patients were followed up for six
months following surgery.
Wickham 2007 recruited 641 patients from two specialised vit-
reoretinal units with rhegmatogenous retinal detachment, under-
going primary vitrectomy with gas tamponade. All patients were
over 16 years of age, and unlike Asaria 2001, also included patients
who were not viewed at being at risk of developing postoperative
PVR. Additional exclusion criteria to Asaria 2001 included giant
retinal tears (defined as peripheral retinal tears greater than three
clock hours in circumferential extent), intended silicone oil tam-
ponade and no light perception preoperative vision.
Types of interventions
In Asaria 2001 and in Wickham 2007 patients in the treatment
group received a continuous infusion of 5-FU (200 ug/ml) and
LMWH (5 IU/ml). Normal saline was used as the infusion in the
placebo group. In Wickham 2007, silicone oil use was counted as
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a protocol violation and these patients were included for analysis.
The number of protocol violations was similar between the two
groups (N=15 in the treatment group and N=18 in the placebo
group), so this is unlikely to have caused significant bias.
In Asaria 2001, if the operation lasted for more than one hour the
infusion bag was replaced with a new identical infusion, whereas
in Wickham 2007, the infusion bag was replaced with Hartmann
solution irrespective of the group.
All patients underwent standard three-port pars plana vitrec-
tomy, with retinopexy using endolaser, indirect laser or cryother-
apy where appropriate. Internal tamponade was achieved with ei-
ther perfluoropropane (C3F8) gas or sulphur hexafluoride (SF6)
gas. Silicone oil was used when indicated in Asaria 2001.
Types of outcome measures
In Asaria 2001, the primary outcome measure was postoperative
PVR, defined as PVR greater than CP1 according to the new
Retinal Society Classification. Secondary outcome measures were
reoperation rate, change in visual acuity and complication rates.
Treatment success was defined as complete retinal reattachment
and no reoperations within six months.
In Wickham 2007, the primary outcome measure was retinal
reattachment after primary vitrectomy without reoperation at six
months. Secondary outcome measures were occurrence and grade
of PVR (grade C and above), best corrected visual acuity, intraoc-
ular pressure, corneal clarity and complications.
Excluded studies
We excluded two studies. One study (Wang 2006) appeared to
meet our inclusion criteria from the abstract. The rest of the study
was published in Chinese. We contacted Dr. Wang Yong directly
who confirmed that the studywas not anRCTand so was excluded
from the review. The second study, Scheer 2005 was rejected after
reviewing the full copy as it was not an RCT.
See the ’Characteristics of excluded studies’ table for further de-
tails.
Risk of bias in included studies
See Figure 1.
Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
In both studies, randomisation was carried out after patients had
been scheduled for surgery and recruited and was performed with
the help of a medical statistics support office. A randomisation
schedule was used by the pharmacy department who then dis-
pensed coded vials of treatment drugs or placebo.
Blinding
In both studies, the patients and surgeons were masked (blinded)
to the type of infusion fluid being used.
Incomplete outcome data
In both studies data were analysed according to the group to which
patients were assigned (i.e. on an intention-to-treat basis).
In Asaria 2001, data for 5/87 patients in the placebo group and
2/87 patients in the treatment group were missing at three and
six month follow up examinations. A simulation on these data
as described in the ’Data collection and analysis’ section did not
substantially change the results.
In Wickham 2007, six month follow up data was incomplete for
15/342 patients in the treatment group and 11/299 patients in the
placebo group.We suggest there is no need to carry out simulations
on the impact of missing data since the loss was balanced and its
causes were also similar and unlikely to be related to treatment
outcome (surgery cancelled or patient did not attend or withdrew
consent, death).
Selective reporting
The primary outcome of this review was reported by both studies
included in this review using the same definition. Re-operation
rates were also reported. Visual acuity change was defined differ-
ently in the two studies: Asaria 2001 used a three-level categori-
sation (worse, stable, better), while Wickham 2007 reported con-
tinuous logMAR visual acuity as median and interquartile range.
Thus, there is potential selective reporting, but only regarding this
secondary outcome in our review.
We could not investigate publication bias due to the fact that only
two studies are included in the review.
Effects of interventions
5-Fluorouracil and LWMH versus placebo
Primary outcome: postoperative PVR
We did not perform a meta-analysis since Asaria 2001 and
Wickham 2007 yielded estimates of effect in the opposite direc-
tion which were heterogeneous (Chi2 test for heterogeneity P =
0.02 and I2 82% in Analysis 1.1). Only Asaria 2001 yielded a
statistical significant difference favouring LMWH with 5-FU.
Secondary outcomes:
1. Reoperation rates
High heterogeneity between Asaria 2001 andWickham 2007 was
also seen for reoperation rates (Chi2 test for heterogeneity P = 0.08
and I2 67% in Analysis 1.2), but in this case neither study yielded
a statistically significant difference between the two groups.
2. Change in visual acuity
The two included studies reported visual acuity differently.
We could extract the proportion of people in whom visual acuity
had worsened at the last examination from Asaria 2001, and the
comparison favoured LMWH with 5-FU (Analysis 1.3).
In Wickham 2007, data were presented as median and interquar-
tile range (IQR). Since there was little evidence of skewness (i.e.
the median was roughly centred in the IQR), we used it to ap-
proximate means and we used IQR as an estimate of standard de-
viation (times 1.35 as suggested in Higgins 2009). After such data
manipulation we could not show a difference between LMWH
with 5-FU and placebo (Analysis 1.4).
3. Complications
In Asaria 2001, five patients developed postoperative hyphaema
in each group, all of which weremild and settled with conservative
treatment. One retinal incarceration and one choroidal haemor-
rhage occurred in the treatment group.
InWickham 2007, choroidal haemorrhage occurred in one patient
in both the placebo and treatment groups. Twopatients had retinal
incarceration in the treatment group.
D I S C U S S I O N
Summary of main results
Although two trials were included in this review, we did not per-
formmeta-analysis because of statistical heterogeneity between the
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trials for both the primary and the secondary anatomic outcome.
This is further substantiated by clinical heterogeneity due to in-
clusion criteria leading to very different preoperative viewed risk
of developing postoperative PVR. Such different inclusion criteria
lead to different rates of PVR in the control group of each study
(26% for Asaria 2001 and 5% for Wickham 2007). The fact that
only Asaria 2001 found LMWH with 5-FU beneficial to prevent
postoperative PVRcould be ascribed to an interaction of treatment
with baseline risk, i.e. the control event rate. The rationale for this
difference would be that LMWH with 5-FU infusion would only
be effective in preventing postoperative PVR in patients under-
going primary vitrectomy for rhegmatogenous retinal detachment
who were viewed at high-risk of developing postoperative PVR,
whereas in cases of rhegmatogenous retinal detachment at low risk
of PVR development its use might be associated with a worse vi-
sual outcome in macular sparing detachments as there are con-
cerns about the use of a cytotoxic agent in a continuous infusion
such as 5-FU.
However, the hypothesis of an interaction between baseline risk
and treatment effect cannot be tested formally in subgroup analysis
in our review with only two included studies, so this explanation
remains presumptive.
Overall completeness and applicability of
evidence
The heterogeneous results of the two studies regarding the direc-
tion of the effect for the primary outcome may suggest that het-
erogeneity is to be expected in studies on the use of LMWHand 5-
FU to prevent PVR during vitrectomy. This is in agreement with
the fact that this is a complex surgical procedure which can be
applied to very different patients. Thus, the evidence collected in
this review is largely incomplete and insufficient to guide clinical
practice.
Quality of the evidence
Overall, the studies were good quality, but the inconsistency of
their results makes any conclusion difficult to be drawn.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently inconsistent evidence from randomised con-
trolled trials on the efficacy of LMWH with 5-FU infusion to
prevent PVR after vitrectomy for retinal detachment.
Implications for research
Future research on LMHW and 5-FU during vitrectomy should
be conducted on patients at high risk of PVR, both because there
are ethical and theoretical reasons favouring this choice and to
enhance study power. Studies on low risk patients should be a
later step if treatment is found beneficial in studies on high risk
patients.
Furthermore, a 2x2 block design may be used to investigate the
separate effect of 5-FU or LMWH as well as their interaction. In
addition, trials looking at the use of a LMWH combined with an
intravitreal 5-FU injection at the end of a vitrectomy procedure,
would be helpful in identifying routes and doses of administration
of therapies that help prevent postoperative PVR in high-risk cases,
and are also universally considered as safe approaches.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Asaria 2001
Methods Double masked, prospective, randomised, placebo-controlled clinical trial
Participants 174 participants with rhegmatogenous retinal detachment who were also viewed at high-
risk of developing postoperative PVR, undergoing primary vitrectomy
Interventions Treatment group received a continuous intraocular LMWH and 5-FU infusion. Placebo
group received normal saline infusion
Outcomes Treatment group had significantly lower postoperative PVR rates
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisationwas carried out after the pa-
tient had been scheduled for surgery and
recruited. Randomisation was performed
with the help of the medical statistics sup-
port office, and a randomisation sched-
ule was sent to the pharmacy department,
which dispensed coded vials of treatment
drugs or placebo
Allocation concealment? Yes Coded vials of treatment or placebo were
added to infusion bag just prior to surgery
Blinding?
Participants
Yes Participants masked (blinded) throughout
study and treatment allocation only re-
vealed at end of study
Blinding?
Surgeons
Yes Surgeons masked throughout study and
treatment allocation only revealed at end of
study
Incomplete outcome data addressed?
All outcomes
Yes Follow-up good and similar between both
groups. 94.3% of participants in the
placebo group and 97.7% of participants
in the treatment group completed the six
month follow-up visit
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Asaria 2001 (Continued)
Free of selective reporting? Yes Selective reporting is not an issue for the
primary outcome “development of PVR”,
or the secondary outcome “reoperation
rate”. It may be an outcome only for the
secondary outcome “visual acuity” as this is
a more subjective assessment and was de-
fined differently in both included studies
Wickham 2007
Methods Double masked, prospective, randomised, placebo-controlled clinical trial
Participants 641 participants with rhegmatogenous retinal detachments from two specialist vitreo-
retinal units, with all participants undergoing primary vitrectomy
Interventions Treatment group received a continuous intraocular LMWH and 5-FU infusion. Placebo
group received normal saline infusion
Outcomes No significant difference in PVR rates between the two groups. Macular sparring de-
tachments who received the LMWH and 5-FU infusion had a significantly worse visual
acuity
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes After recruitment, non-trial personnel ran-
domised participants on the day of surgery
to the treatment or placebo groups using a
computer generated weighted coinmethod
Allocation concealment? Yes Randomisation code kept on separate com-
puter from investigators and pre-prepared
coded infusion fluid used
Blinding?
Participants
Yes Participants masked throughout and treat-
ment allocation only revealed at end of
study
Blinding?
Surgeons
Yes Surgeons masked throughout and treat-
ment allocation only revealed at end of
study
Incomplete outcome data addressed?
All outcomes
Yes Follow-up good and similar between both
groups. 96.3% of participants in the
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Wickham 2007 (Continued)
placebo group and 95.6% of participants
in the treatment group completed the six
month follow-up visit. Causes were also
similar in the two groups and also un-
likely to be related to treatment outcome
(surgery cancelled, participant did not at-
tend or withdrew consent, death)
Free of selective reporting? Yes Selective reporting is not an issue for the
primary outcome “development of PVR”,
or the secondary outcome “reoperation
rate”. It may be an outcome only for the
secondary outcome “visual acuity” as this is
a more subjective assessment and was de-
fined differently in both included studies
5-FU: 5-Fluorouracil
LMWH: low molecular weight heparin
PVR: proliferative vitreoretinopathy
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Scheer 2005 Not a randomised controlled trial.
Wang 2006 Not a randomised controlled trial.
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